Non-Hodgkin lymphoma survival doubles since early 1970s

May 23, 2013, Cancer Research UK
Non-Hodgkin lymphoma survival doubles since early 1970s

More than half of patients diagnosed with Non-Hodgkin Lymphoma (NHL) are now surviving the disease thanks to improved diagnosis and treatment, according to a new report1 from Cancer Research UK.

The report, co-authored with the Haematological Research Network (HMRN) and supported by Leukaemia & Lymphoma Research, shows that NHL rates have doubled since the early 1970s, when less than a quarter survived their disease for at least 10 years. And it predicts more than half of those diagnosed today will survive the disease for this long.

These vast improvements are largely thanks to better treatments – particularly the drug rituximab, which Cancer Research UK scientists laid the groundwork for with their early work into the immune system – and earlier linked to improved understanding of the disease.

Non-Hodgkin lymphomas are a group of diseases that affect white blood cells – the cells that normally defend the body against infection. In NHL patients, these cells stop working properly, too many are produced and they can collect together to form tumours. The causes of NHL remain largely unknown, although problems with the immune system are thought to be involved.

Dr Russell Patmore, consultant haematologist at Hull and East Yorkshire Hospitals NHS Trust and one of the report's authors, said: "Years of research have improved our understanding of NHL and how best to treat it. We now know there are more than 20 sub-types of the disease, each with their own distinct patterns of incidence and prognosis. And by knowing which type we're dealing with, treatment can be tailored so it has the greatest benefit to patients."

The Cancer Research UK report also presents the first population-based estimates of survival for some of the sub-types of the disease.

The analysis reveals huge variation by NHL sub-type. For example, patients diagnosed with mantle cell lymphoma – a rare but aggressive sub-type – have only a one in four chance of surviving for more than five years.

By contrast, around nine in 10 people diagnosed with follicular lymphoma, which is more common and develops more slowly, survive for at least five years.

Dr Patmore added: "When we know the type of lymphoma we're dealing with, we can use more targeted therapies like rituximab. This has been one of the key drugs for NHL patients in recent years and is largely responsible for the survival improvements in the more common forms of the disease.

"It's important that future research focuses on early detection and classification of sub-types, as well as improving the quality of life for people living with the disease."

NHL is the sixth most common cancer in the UK, with more than 12,000 new cases diagnosed each year.

Catherine Thomson, head of statistics at Cancer Research UK, said: "This report presents the first population-based estimates of survival by sub-type and we're seeing there are clear differences in outlook depending on which sub-type you have.

"As well as disease type, we know that age, sex and the stage at which you're diagnosed all play their parts in predicting the chances of survival. But the overall picture is positive compared with the early 1970s and research is helping to improve things today.

"Our researchers made major contributions to the early understanding of the and their work laid the foundations for the development of rituximab, which is now the first-line treatment for most NHL patients."

Explore further: Differences in staging and treatment likely to be behind UK's low bowel cancer survival

More information: Cancer Research UK (2013) Cancer Statistics Report: Non-Hodgkin Lymphomas - UK: … ncerstats/types/nhl/

Related Stories

Differences in staging and treatment likely to be behind UK's low bowel cancer survival

April 16, 2013
Incomplete diagnostic investigation and failure to get the best treatment are the most likely reasons why survival for bowel cancer patients is lower in the UK than in other comparable countries, according to new research ...

Improved treatments for chronic myeloid leukaemia have dramatically increased survival

December 12, 2012
Survival for people diagnosed with Chronic Myeloid Leukaemia (CML) has risen by nearly half, with around 58 per cent of people surviving their disease for at least five years compared with only around 40 per cent in the late ...

Celiac disease linked to lymphoproliferative disorders

July 26, 2012
(HealthDay) -- Patients with celiac disease, particularly those presenting with malabsorption symptoms later in life, have a higher incidence of lymphoproliferative disorders (LPDs), according to research published in the ...

Risk of leukemia after cancer chemotherapy persists

February 14, 2013
While advancements in cancer treatment over the last several decades have improved patient survival rates for certain cancers, some patients remain at risk of developing treatment-related leukemia, according to results of ...

New research seeks to improve survival for myeloma and lymphoma patients

July 25, 2012
Researchers at the University of York are launching a major study of lymphoma and myeloma aimed at promoting earlier diagnosis and improving survival for patients with these cancers, which are among the most common in the ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.